Dr. Reddy's Laboratories Limited American Depositary Shares
RDY$14.18 +0.24 (1.72%)
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| $0.11 | 2003-08-07 | 2003-08-11 | |
| August 6, 2025 | $0.09 | 2025-07-25 | 2025-07-10 |
| August 12, 2024 | $0.48 | 2024-07-30 | 2024-07-15 |
| August 11, 2023 | $0.48 | 2023-07-28 | 2023-07-10 |
| August 12, 2022 | $0.38 | 2022-08-01 | 2022-07-11 |
Dividends Summary
- The most recent dividend was paid 136 days ago, on August 6, 2025
- The highest dividend payed out to investors during this period was $0.48 per share
- The average dividend paid during this period was $0.24 per share.
Company News
FDA Weighs Rapid Review For Eli Lilly Obesity Pill As Novo Nordisk Nears Launch
The FDA is considering expediting the review process for Eli Lilly's experimental oral weight-loss treatment, orforglipron, potentially moving the decision date to late March. Rival Novo Nordisk is preparing to launch its own weight-loss pill in December or January.
Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy’s Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040
Esperion has settled patent litigation with Dr. Reddy's Laboratories, agreeing that generic versions of NEXLETOL and NEXLIZET will not be marketed in the US before April 19, 2040.
Dr. Reddy's (RDY) to Acquire Haleon's Nicotine Addiction Drug
Dr. Reddy's (RDY) is set to acquire Haleon's leading global NRT brand, Nicotinell, and its related portfolio across all formats of the drug for GBP 500 million to boost its OTC presence worldwide.
The success of Merck's antiviral — and other COVID-19 pills in development — may depend on how quickly people start taking them
That may mean starting treatment within days after testing positive for the virus.
